Weill Cornell Breast Center: List of Open Clinical Trials

Below is a complete list of open clinical trials at the Weill Cornell Breast Center. Click on the study name to read detailed information about the study. To find out more about our clinical trials or to make an appointment at the Breast Center, please call (212) 821-0644.

Supportive Care/Non-Treatment Studies

Study Name Goal of Study Eligibility
Cold Cap Study Preventing hair-loss using the Cold Cap during Taxotere/Cytoxan (TC) -Early Stage Breast Cancer-Begins with TC chemotherapy
Glutamine Study Reducing peripheral neuropathy using glutamine -Grade 1 or above neuropathy-During or after Taxol or Abraxane.
Herceptin Cardiotoxicity Evaluating variations in DNA sequencing (SNPs) on risk of Herceptin-related heart failure -Congestive heart failure-Decline in ejection fraction by 15%
Rakhi Study To study how breast tumors develop blood vessels -Blood samples during treatment-Already underwent surgery

Treatment Studies

Study Name Goal of Study Eligibility
GALENA A vaccine trial: evaluating NeuVax in preventing breast cancer recurrence. -HER2 1+/2+, node positive-Completed standard treatment with surgery, chemo, radiation.
PUMA To study the benefit of two new drugs: Temsirolimus plus Neratinib in metastatic HER2 or TNBC* -No more than 4 prior chemo regimen-Received Herceptin in the past-No concurrent use of hormone therapy
RxSPONDER To study how hormone therapy work with or without chemotherapy in breast cancer -Hormone Positive, HER2 negative-Oncotype <25, 1-3 lymph node positive
BEACON New generation TOPO1 inhibitor NKTR-102 (targets tumor DNA) in recurrent or metastatic breast cancer -Already received 2-5 prior regimens-Already received Taxane, anthracycline, Xeloda, Herceptin (if HER2 +), and hormone therapy (if ER+)
IMMU-132 To study the effectiveness of antibody RS7 attached to SN38, a metabolite of Irinotecan -Already received 1-3 prior regimens-Active disease on CT or MRI
OPTIMER Immunotherapy with OPT-822 in metastatic breast cancer -Stable disease, partial response, or complete response after 1 regimen
ALLIANCE Using Panobinostat (blocks enzymes needed for cell growth) and Letrozole in TNBC* -TNBC* with metastatic disease
177-J591 Using an antibody J591 linked to radioactive molecule 177Lu, to target tumor blood vessels -Metastatic breast cancer-Already received standard therapy
SYNTA Using Ganetespib, a small molecule inhibitor against Hsp90 protein, to stop tumor growth -Previously untreated metastatic, HER2 positive, or TNBC*.
LUX-Breast 1 Using Afatinib (inhibits growth factor receptor) plus Navelbine vs. Herceptin plus Navelbine to stop tumor growth -HER2 positive, metastatic disease-Failed one prior treatment-No prior Navelbine
BKM120 Using BKM120 (inhibit tumor growth and survival by blocking PI3K pathway) with fulvestrant, to enhance cancer cell death -Metastatic, Hormone positive-HER2 negative-Progressed on or after aromatase inhibitor
NCI8264 Using PARP inhibitor ABT-888 (interfere with tumor DNA repair) alone or with Carboplatin -Metastatic BRCA-associated breast cancer
TM Using TM (copper depletion) to prevent recurrence in moderate to high risk patients -Metastatic no active disease-Stage 2 and above TNBC*.

*TNBC = Triple Negative Breast Cancer

Weill Cornell’s Dr. Ellen Chuang Does Breast Cancer Q&A on TalkAboutHealth.com

Ellen Chuang, MD

The Breast Center’s Ellen Chuang, MD is currently doing a breast cancer Q and A on the website TalkAboutHealth.com.

Some sample questions:

1. Are the breast cancer sub-types different among Asian ethnic groups? What do we know about the differences? Click here to read Dr. Chuang’s answer.

2. For Stage 1 breast cancer, what factors determine if chemotherapy is recommended? Click here to read Dr. Chuang’s answer.

Use this link to register with TalkAboutHealth and post a question for Dr. Chuang. Click here to view all the questions and answers posted so far.

Dr. Chuang is an Associate Professor of Clinical Medicine, Weill Cornell Medical College and an Associate Attending Physician, NewYork-Presbyterian Hospital. She is a board-certified medical oncologist.

Weill Cornell Research: Breast Cancer Subtypes in Asian-Americans Differ Among Asian Ethnic Groups

Breast cancer prognosis and breast cancer subtypes vary by race/ethnicity. Researchers at Weill Cornell Medical College, led by Dr. Ellen Chuang of the Weill Cornell Breast Center, explored whether the distribution of breast cancer subtypes varies among different Asian ethnic groups.

Analyzing the subtypes of 346 Asian patients treated at two New York City hospitals, the researchers found that Chinese and Japanese patients had a higher proportion of good-prognosis luminal A cancers, compared to Filipinos and Koreans. Filipinos had a higher proportion of HER-2/neu positive cancer compared to other ethnic groups. Koreans had a higher proportion of triple negative cancers compared to other ethnic groups.

Over 6000 cases of breast cancer are diagnosed yearly in Asian women in the US. The results of this study have implications for the health of Asian Americans with breast cancer. They suggest that Filipinos are more likely to have a type of breast cancer that is more aggressive and require prolonged therapy, whereas Chinese and Japanese women have a more favorable subtype of breast cancer which, if found in its earliest stages, may be treated with hormonal therapy alone. It is not known why these differences exist, whether they have underlying genetic factors or are related to environmental factors such as diet and lifestyle.

Click here to read the published research paper.